Loading the state's markets…
Loading the state's markets…
Loading the market…
Medicare market size, surgeons and outlook to 2030
Medicare fee-for-service bone graft & orthobiologics cases in North Carolina: reported (2020, the pandemic year, left out of the line), then forecast with its 80% range. One year ahead, this procedure’s market forecast has been off by 12% on average (190 state-years, 2020–2024): read it as a direction with a margin.
| Year | Surgeons | Medicare FFS | Advantage share |
|---|---|---|---|
| 2019 | 34 | 1,138 | 40% |
| 2020 | 21 | 864 | 43% |
| 2021 | 19 | 780 | 48% |
| 2022 | 20 | 647 | 52% |
| 2023 | 16 | 605 | 56% |
| 2024 | 14 | 525 | 59% |
| 2025 from claims | – | 510 412–599 | 61% |
| 2026 forecast | – | 514 402–645 | 62% |
| 2027 forecast | – | 515 382–681 | 62% |
| 2028 forecast | – | 516 365–712 | 63% |
| 2029 forecast | – | 517 351–741 | 64% |
| 2030 forecast | – | 517 339–768 | 65% |
Graft add-on codes identify surgeons using biologics across spine and extremity cases. Professional codes (what the surgeon bills): CPT 20930, 20931, 20936, 20937, 20938, 20939.
Surgeons and fee-for-service cases are from CMS’s Medicare Physician & Other Practitioners files, counted where the surgeon billed; state totals include the cases CMS leaves out of the surgeon-level file (under 11 patients). All Medicare adds patients in Medicare Advantage at the state’s enrollment share; all payers scales Medicare by its share of the procedure nationally. The forecast carries cases per resident 65+ forward with the Census projection of residents 65+. How the numbers are made · Data sources
The 10 busiest do 85% of the cases CMS names in North Carolina; 9 surgeons do 80% of them.
MedaRep names every one, ranked by volume, with their practice, hospitals, trend, forecast and which device companies already engage with them.
In 2025, 74% inpatient hospital, 24% hospital outpatient, 2% surgery center.
| State | Surgeons | Medicare FFS | Growth since 2019 | Per 1,000 | Out of hospital | Forecast |
|---|---|---|---|---|---|---|
| Texas | 52 | 1,980−11%/yr | −11%/yr | 0.9 | 3% | 1,960 in 2030−0.1%/yr |
| Florida | 34 | 1,353−8.3%/yr | −8.3%/yr | 0.6 | 6% | 1,490 in 2030+1.6%/yr |
| Georgia | 15 | 773−3.8%/yr | −3.8%/yr | 0.9 | 5% | 720 in 2030−1.3%/yr |
| Virginia | 17 | 601−14%/yr | −14%/yr | 0.6 | 0% | 650 in 2030+1.2%/yr |
| Tennessee | 16 | 498−9.2%/yr | −9.2%/yr | 0.7 | 3% | 450 in 2030−1.8%/yr |
| Arkansas | 8 | 484−8.7%/yr | −8.7%/yr | 1.2 | 2% | 370 in 2030−4.3%/yr |
| Maryland | 14 | 451−8%/yr | −8%/yr | 0.5 | 4% | 370 in 2030−3.3%/yr |
| South Carolina | 13 | 440−13%/yr | −13%/yr | 0.6 | 1% | 450 in 2030+0.5%/yr |
| Oklahoma | 13 | 397−18%/yr | −18%/yr | 0.8 | 1% | 430 in 2030+1.3%/yr |
| Louisiana | 8 | 369−1.6%/yr | −1.6%/yr | 0.9 | 1% | 360 in 2030−0.5%/yr |
| Delaware | 7 | 334−2.8%/yr | −2.8%/yr | 1.9 | 11% | 340 in 2030+0.5%/yr |
| Alabama | 10 | 293−20%/yr | −20%/yr | 0.6 | 4% | 290 in 20300%/yr |
| Kentucky | 7 | 228−18%/yr | −18%/yr | 0.5 | 0% | 260 in 2030+2.1%/yr |
| Mississippi | 5 | 119−17%/yr | −17%/yr | 0.3 | 11% | 90 in 2030−4.7%/yr |
| Surgeons | Medicare FFS | Growth since 2019 | Per 1,000 | Out of hospital | Forecast | |
|---|---|---|---|---|---|---|
| Debridement & negative-pressure wound therapy | 411 | 84,720−6.3%/yr | −6.3%/yr | 81.10.7× | 34% | 87,500 in 2030+0.5%/yr |
| Skin substitutes & wound grafts | 35 | 7,475+4.4%/yr | +4.4%/yr | 4.40.4× | 66% | 10,800 in 2030+6.4%/yr |
Bone graft & orthobiologics in every state, and its device makers · Every procedure market in North Carolina · Every state · Compare with Texas
Bausch & Lomb leads with 56% of company spending on these surgeons in 2025, −11 pts on 2024.
In 2025, 13 companies reported engagement with North Carolina’s surgeons worth $320K in consulting, speaking, meals and travel tied to these products, about $23K per surgeon billing it. Royalties are left out.
FDA, last 12 months: 14 clearances and approvals in the category, 6 recalled product lines. A recall is a public FDA notice, not a finding of fault.
Which surgeons each company engages, and the dollars reported, are in the ranking. Open Payments shows the payments companies reported. It suggests engagement, not which devices a surgeon uses, and is not evidence of wrongdoing. Every company in the category.
Share of the cases CMS names by surgeon, by where they billed. Open one for its ranking.
For CPT 20931 (sp bone algrft struct add-on), commercial plans pay North Carolina’s hospitals a median of $112, from $112 at the lowest to $112 at the highest, across 3 hospitals that publish a price.
Each hospital’s median over its commercial plans, from the machine-readable files hospitals must post; not every hospital is loaded.